P. Banfi

发表

Protein kinase C activation by anthracyclines in swiss 3T3 cells

F. Zunino, C. Lanzi, P. Perego, 1991, International journal of cancer.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

R. Bosotti, A. Isacchi, A. Bardelli, 2015, Journal of the National Cancer Institute.

Modulation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor.

F. Zunino, P. Perego, P. Banfi, 1991, Cancer letters.

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Andrea Lombardi Borgia, Antonella Isacchi, Roberta Bosotti, 2014, Molecular oncology.

Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .

A. Isacchi, A. Galvani, P. Orsini, 2013 .

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.

A. Isacchi, A. Galvani, E. Pesenti, 2011 .

Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets.

C. Lanzi, R. Gambetta, F. Ravagnani, 1988, Biochemical pharmacology.

Structure-based optimization of potent PDK1 inhibitors.

E. Casale, F. Zuccotto, M. Angiolini, 2010, Bioorganic & medicinal chemistry letters.

Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.

Becky Penhallow, Andrew Tebben, Jonathan Lippy, 2012, Bioorganic & medicinal chemistry letters.

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

A. Isacchi, G. Canevari, E. Felder, 2016, Journal of medicinal chemistry.

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.

M. Modugno, D. Ballinari, W. Pastori, 2015, Experimental cell research.

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

R. Bosotti, A. Isacchi, E. Felder, 2016, Molecular Cancer Therapeutics.

The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines.

M. Gariboldi, T. Dragani, C. Lanzi, 1994, Molecular pharmacology.

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.

Andrew Tebben, Jonathan Lippy, Michele Modugno, 2012, Bioorganic & medicinal chemistry letters.

Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes

F. Zunino, R. Supino, R. Gambetta, 1994, International journal of cancer.

Lipid peroxidation, phosphoinositide turnover and protein kinase C activation in human platelets treated with anthracyclines and their complexes with Fe(III).

C. Lanzi, R. Gambetta, O. Parolini, 1992, Biochemical pharmacology.

310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101

M. Ciomei, A. Galvani, E. Ardini, 2014 .

Protein Kinase C Activation and Lipid Peroxidation by Doxorubicin Analogues

F. Zunino, C. Lanzi, R. Gambetta, 1989, Tumori.

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

A. Isacchi, G. Canevari, E. Felder, 2019, Journal of medicinal chemistry.

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

A. Isacchi, E. Felder, A. Borgia, 2018, Experimental and Molecular Therapeutics.